September 11, 2026Joseph M. Diehl, Christina Chwyl, Liliana Kennedy et al.
preprint
The therapeutic relationship is considered central to psychedelic-assisted therapy, yet little empirical research has examined how it changes during 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) or relates to acute MDMA experiences and clinical outcomes, particularly for social anxiety disorder (SAD). This preregistered secondary analysis examined therapeutic alliance and...
Background: ±3,4-methylenedioxymethamphetamine (MDMA) has positive effects on socio-emotional processing and MDMA-Assisted Therapy (MDMA-AT) showed promise for treating SAD in a previous placebo-controlled trial. Aims: Develop a preliminary estimate of clinical response and safety for MDMA-AT versus waitlist in adults with SAD. Secondary aims included refinement of a standardized psychotherapy...
The use of supportive touch in psychedelic-assisted therapy (PAT) and MDMA-assisted therapy (MDMA-AT) presents unique ethical challenges and opportunities. While touch can be a valuable component of treatment, its implementation requires careful consideration due to the altered states of consciousness induced by psychedelics and the potential for boundary violations. This paper addresses a...
Neitzke-Spruill et al. (2025) offer an important overview of the ethical considerations around the use of touch within psychedelic assisted therapies (PAT) and MDMA-assisted therapy (MDMA-AT). Thei...